Occurrence of COVID-19 in priority groups receiving ChAdOx1 nCoV-19 coronavirus vaccine (recombinant): a preliminary analysis from north India.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of medical virology"
DOI: 10.1002/jmv.27320
Abstract: The ChAdOx1 nCoV-19 vaccine (Oxford University-Astra Zeneca) has demonstrated nearly 70% efficacy against symptomatic COVID-19 in trials and some real-world studies. The vaccine was the first to be approved in India in early January 2021… read more here.
Keywords: preliminary analysis; chadox1 ncov; occurrence; covid ... See more keywords
Acute Arterial Occlusion Following ChAdOx1 nCov-19 (Oxford–AstraZeneca) Vaccination
Sign Up to like & getrecommendations! Published in 2022 at "Cardiovascular and Interventional Radiology"
DOI: 10.1007/s00270-021-03053-3
Abstract: To the Editor, there have been documented cases of rare thrombotic events associated with venous thrombosis and thrombocytopenia post vaccination with ChAdOx1 nCov19 (Oxford-AstraZeneca COVID-19 Vaccine). This phenomenon was termed vaccine-induced immune thrombotic thrombocytopenia (VIITT)… read more here.
Keywords: chadox1 ncov; vaccination; oxford astrazeneca; acute arterial ... See more keywords
Post ChAdOx1 nCoV-19 vaccination frontal lobe syndrome
Sign Up to like & getrecommendations! Published in 2022 at "Neurological Sciences"
DOI: 10.1007/s10072-022-06086-9
Abstract: Dear Editor, The stepping up of an effective mass vaccination programme against the novel SARS-CoV-2 virus worldwide has led to the emergence of a host of adverse events involving various systems, a majority of which… read more here.
Keywords: lobe syndrome; frontal lobe; ncov vaccination; chadox1 ncov ... See more keywords
A comprehensive review on COVID-19 vaccines: development, effectiveness, adverse effects, distribution and challenges
Sign Up to like & getrecommendations! Published in 2022 at "VirusDisease"
DOI: 10.1007/s13337-022-00755-1
Abstract: The present SARS-CoV-2 induced COVID-19 pandemic is responsible for millions of deaths, illnesses, and economic loss worldwide. There are 21 COVID-19 vaccines from different platforms approved worldwide for emergency use until 13 August 2021. Later,… read more here.
Keywords: chadox1 ncov; sars cov; covid vaccines; adverse effects ... See more keywords
Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants
Sign Up to like & getrecommendations! Published in 2022 at "EBioMedicine"
DOI: 10.1016/j.ebiom.2021.103761
Abstract: Background Heterologous COVID-19 vaccination regimens combining vector- and mRNA-based vaccines are already administered, but data on solicited adverse reactions, immunological responses and elicited protection are limited. Methods To evaluate the reactogenicity and humoral as well… read more here.
Keywords: chadox1 ncov; boost; sars cov; vaccination ... See more keywords
Prevalence of Covishield COVID-19 Vaccine (ChAdOx1 nCoV-19) Adverse Effects among Health Care Workers in Sri Lanka
Sign Up to like & getrecommendations! Published in 2022 at "International Journal of Infectious Diseases"
DOI: 10.1016/j.ijid.2021.12.143
Abstract: Purpose A Community vaccination programme is the best approach to combat COVID-19 pandemic. The first priority was given to the health care workers (HCWs) with the introduction of Indian Covishield (ChAdOx1 nCoV-19) vaccine to Sri… read more here.
Keywords: chadox1 ncov; sri lanka; health care; covishield ... See more keywords
Increased neutralization of SARS-CoV-2 Delta variant after heterologous ChAdOx1 nCoV-19/BNT162b2 versus homologous BNT162b2 vaccination
Sign Up to like & getrecommendations! Published in 2022 at "iScience"
DOI: 10.1016/j.isci.2021.103694
Abstract: Heterologous SARS-CoV-2 vaccine approaches with a second mRNA-based vaccine have been favored in the recommendations of many countries over homologous vector-based ChAdOx1 nCoV-19 vaccination after reports of thromboembolic events and lower efficacy of this regimen.… read more here.
Keywords: chadox1 ncov; bnt162b2; sars cov; vaccination ... See more keywords
Comparison of vaccine-induced thrombotic events between ChAdOx1 nCoV-19 and Ad26.COV.2.S vaccines
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Autoimmunity"
DOI: 10.1016/j.jaut.2021.102681
Abstract: Cerebral venous thrombosis (CVT) events have been reported after vaccination with adenoviral COVID-19 vector vaccines. This study aimed to compare the clinical presentations and courses of vaccine-induced thrombotic thrombocytopenia (VITT) between the two adenoviral vector… read more here.
Keywords: comparison vaccine; chadox1 ncov; ad26 cov; vaccine induced ... See more keywords
Treatment of ChAdOx1 nCoV-19 Vaccine-Induced Immune Thrombotic Thrombocytopenia Related Acute Ischemic Stroke
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Stroke and Cerebrovascular Diseases"
DOI: 10.1016/j.jstrokecerebrovasdis.2021.106072
Abstract: Recently cases of vaccine-induced immune thrombotic thrombocytopenia (VITT) and thrombosis following the adenoviral vector vaccine against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were reported. A mechanism similar to heparin-induced thrombocytopenia was proposed with… read more here.
Keywords: treatment; chadox1 ncov; induced immune; vaccine induced ... See more keywords
ChAdOx1 nCoV-19 (AZD1222) vaccine candidate significantly reduces SARS-CoV-2 shedding in ferrets
Sign Up to like & getrecommendations! Published in 2021 at "NPJ Vaccines"
DOI: 10.1038/s41541-021-00315-6
Abstract: Vaccines against SARS-CoV-2 are likely to be critical in the management of the ongoing pandemic. A number of candidates are in Phase III human clinical trials, including ChAdOx1 nCoV-19 (AZD1222), a replication-deficient chimpanzee adenovirus-vectored vaccine… read more here.
Keywords: chadox1 ncov; candidate; vaccine candidate; ncov azd1222 ... See more keywords
Epidemiology of VITT
Sign Up to like & getrecommendations! Published in 2022 at "Seminars in Hematology"
DOI: 10.1053/j.seminhematol.2022.02.002
Abstract: Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a life-threatening syndrome of aggressive thrombosis, often profound thrombocytopenia, and frequently overt disseminated intravascular coagulation. It has been associated with two adenovirus vector COVID-19 vaccines: ChAdOx1 nCoV-19 (AstraZeneca) and… read more here.
Keywords: vitt; chadox1 ncov; epidemiology vitt; case per ... See more keywords